Cargando...
Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China
BACKGROUND: In this study, we analyze the cost-effectiveness of fruquintinib as third-line treatment for patients with metastatic colorectal cancer in China, especially after a recent price drop suggested by the National Healthcare Security Administration. METHODS: A Markov model was developed to in...
Gardado en:
| Publicado en: | BMC Cancer |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BioMed Central
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7556971/ https://ncbi.nlm.nih.gov/pubmed/33050905 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07486-w |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|